Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the same main ingredient as Mounjaro. The difference is that Mounjaro is for diabetes and Zepbound is for ...

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called GLP-1.

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

Manufactured by Eli Lilly and Company, Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable prescription medication ...